SPRY

ARS Pharmaceuticals, Inc.

$3.57

13.33%
SectorHealthcareIndustryBiotechnologyCountryUnited States

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

Source: Yahoo Finance
AI summary

Price & performance

1M-15.6%
3M-39.6%
YTD-68.9%
1Y-59.8%
52-week range—
Beta1.29
Full chart and returns against a benchmark

Q-Score

42/ 100

Quality against peers; 50 is the peer median.

Growth55
Risk53
Performance42
Valuation39
Profitability35
Leverage34
Sentiment32
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue$84.3M-5.5%
Net income-$171.3M-2241.8%
Net margin-203.3%-212.2 pts
Historical fundamentals

Revenue exposure

14%of revenue from outside the US
United States86%
Non Us14%
Largest customer94%
Regions, segments, customers and suppliers

Valuation

SPRYIndustryP/E—89.69P/S2.9411.88EV/EBITDA—67.10P/B—6.22PEG—4.02
Dividend yield0.00%
Every valuation metric

Earnings

Nov 5next report
EPS estimate$-0.33
Beats (last 4 quarters)—
Average surprise—
EPS revisions (30d)—
Every quarter against its estimate